For families and patients wanting more information about Allo Phase 2 Alzheimer’s Clinical Trial: LEARN MORE

Troubled by hot flashes? Learn more about the HF Relief Study being conducted at the University of Arizona to test the effectiveness of a natural product, PhytoSERM, to alleviate hot flashes:

For information about the PhytoSERM Brain Clinical Trial: LEARN MORE

Is hormone-modulating therapy associated with neurodegenerative disease in women with breast cancer?

A recent study conducted by CIBS researchers and published in the Journal of the American Medical Association (JAMA) found that among patients with breast cancer, tamoxifen and steroidal aromatase inhibitors were associated with a decrease in the number who received a diagnosis of neurodegenerative disease (NDD), specifically Alzheimer’s and dementia.

These findings not only advance knowledge and our ability to prevent, treat and cure cancer, but increase the importance of understanding the long-term outcomes of therapy selection for age-related neurodegenerative diseases.

The fact that breast cancer is the second most common cancer in women (after skin cancer) and that women are disproportionately affected by Alzheimer’s disease and related dementia provide a unique opportunity to reduce the global disease burden of neurodegenerative diseases.

Read the full investigation at JAMA Network | Open:

The Center for Innovation in Brain Science (CIBS) at the University of Arizona is addressing the challenge that, in the 21st century, there is not a single cure for a single neurodegenerative disease and is focused on four age-associated neurodegenerative diseases: Alzheimer’s, Parkinson’s, Multiple Sclerosis and ALS.

© 2024 Center for Innovation Brain Science. University of Arizona Health Sciences.

Skip to content